Rachel Schiff, Ph.D.

Professor

(713) 798-1676

Email

rschiff@bcm.edu

Positions

Professor: Breast Center - Schiff
Baylor College of Medicine
Houston, TX, US

Member: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Professional Interests

Biology of ER-positive and HER2-positive breast cancer, targeted therapies, treatment resistance, correlative biomarkers, integrative OMICS and functional genomics

Professional Statement

My research program focuses on understanding the key signaling pathways in breast cancer and on identifying therapeutic strategies to overcome them, particularly treatments targeting the estrogen receptor and the HER2 receptor. Major research themes include the crosstalk between the ER signaling network and growth factor and cellular kinase pathways, the role of ER co-regulators and pioneer factors in breast cancer development and metastasis, the identification of genomic and epigenomic alterations underlying resistance to endocrine and HER2-targeted therapies, and the development of biomarkers for tailored therapeutic interventions.

Websites

Schiff-Osborne lab

Selected Publications

Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R,. " A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. " Science. 2012 Jan 20; 335 (6066) : 348-53.
Pubmed PMID: 22157079.
Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schi. " Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase. " Cell. 2011 Mar 4; 144 (5) : 703-18.
Pubmed PMID: 21376233.
Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. " Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. " Cancer Chemother. Pharmacol.. 2005 Nov ; 56 : 41567.
Pubmed PMID: 16273359.
Schiff R, Chamness GC, Brown PH. " Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). " Breast Cancer Res.. 2003 ; 5 (5) : 228-31.
Pubmed PMID: 12927029.
Osborne CK, Schiff R. " Aromatase inhibitors: future directions. " J. Steroid Biochem. Mol. Biol.. 2005 May ; 95 (41279) : 183-7.
Pubmed PMID: 16019204.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. " Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. " J. Clin. Oncol.. 2005 Oct 20; 23 (30) : 7721-35.
Pubmed PMID: 16234531.
Schiff R, Massarweh S, Shou J, Osborne CK. " Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. " Clin. Cancer Res.. 2003 Jan ; 9 (1) : 447S-54S.
Pubmed PMID: 12538499.
Schiff R, Lee AV. " Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? " Nat Clin Pract Oncol. 2006 Mar ; 3 (3) : 134-5.
Pubmed PMID: 16520802.
Cheng CM, Li H, Gasman S, Huang J, Schiff R, Chang EC. " Compartmentalized Ras Proteins Transform NIH 3T3 Cells with Different Efficiencies. " Mol. Cell. Biol.. 2011 Mar ; 31 (5) : 983-97.
Pubmed PMID: 21189290.
Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. " Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. " Clin. Cancer Res.. 2004 Jan 1; 10 (1) : 331S-6S.
Pubmed PMID: 14734488.
Osborne CK, Shou J, Massarweh S, Schiff R. " Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. " Clin. Cancer Res.. 2005 Jan 15; 11 (2) : 865s-70s.
Pubmed PMID: 15701879.
Arpino G, Wiechmann L, Osborne CK, Schiff R. " Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. " Endocr. Rev.. 2008 Apr ; 29 (2) : 217-33.
Pubmed PMID: 18216219.
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. " Cytoplasmic estrogen receptor in breast cancer. " Clin. Cancer Res.. 2012 Jan 1; 18 (1) : 118-26.
Pubmed PMID: 21980134.
Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. " Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. " Cancer Res.. 2008 Sep 15; 68 (18) : 7493-501.
Pubmed PMID: 18794137.
Giuliano M, Trivedi MV, Schiff R. " Die and let live: harnessing BikDD to combat breast cancer stem cells. " Breast Cancer Res.. 2012 ; 14 (3) : 310.
Pubmed PMID: 22621279.
Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. " Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. " Mol. Endocrinol.. 2003 Aug ; 17 (8) : 1543-54.
Pubmed PMID: 12730327.
Kang YK, Schiff R, Ko L, Wang T, Tsai SY, Tsai MJ, O'Malley BW. " Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis. " Cancer Res.. 2008 Oct 1; 68 (19) : 7887-96.
Pubmed PMID: 18829545.
Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM. " Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. " J. Nucl. Med.. 2007 Sep ; 48 (9) : 1501-10.
Pubmed PMID: 17785729.
Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. " Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. " Breast. 2005 Dec ; 14 (6) : 458-65.
Pubmed PMID: 16236516.
Schiff R, Osborne CK. " Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. " Breast Cancer Res.. 2005 ; 7 (5) : 205-11.
Pubmed PMID: 16168139.
Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. " Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. " Cancer. 2010 Mar 1; 116 (5) : 1234-42.
Pubmed PMID: 20082448.
Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS. " Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. " Mol. Endocrinol.. 2006 Mar ; 20 (3) : 491-502.
Pubmed PMID: 16306086.
Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. " Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. " Cancer Res.. 2003 May 15; 63 (10) : 2434-9.
Pubmed PMID: 12750263.
Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y. " Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. " Oncogene. 2005 Jun 16; 24 (26) : 4220-31.
Pubmed PMID: 15824740.
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. " Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. " J. Natl. Cancer Inst.. 2005 Sep 7; 97 (17) : 1254-61.
Pubmed PMID: 16145046.
Osborne CK, Schiff R, Fuqua SA, Shou J. " Estrogen receptor: current understanding of its activation and modulation. " Clin. Cancer Res.. 2001 Dec ; 7 (12) : 4338s-4342s; di.
Pubmed PMID: 11916222.
Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J, Lee AV. " Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. " Cancer Res.. 2003 Sep 1; 63 (17) : 5203-8.
Pubmed PMID: 14500345.
Osborne CK, Schiff R. " Estrogen-receptor biology: continuing progress and therapeutic implications. " J. Clin. Oncol.. 2005 Mar 10; 23 (8) : 1616-22.
Pubmed PMID: 15755967.
Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. " Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. " Cancer Res.. 1999 Nov 1; 59 (21) : 5425-8.
Pubmed PMID: 10554010.
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. " Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study. " Clin. Cancer Res.. 2011 Mar 1; 17 (5) : 1147-59.
Pubmed PMID: 21220480.
Osborne CK, Schiff R. " Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. " Breast. 2003 Dec ; 12 (6) : 362-7.
Pubmed PMID: 14659106.
Gutierrez C, Schiff R. " HER2: biology, detection, and clinical implications. " Arch. Pathol. Lab. Med.. 2011 Jan ; 135 (1) : 55-62.
Pubmed PMID: 21204711.
Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. " Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. " Clin. Cancer Res.. 2009 Jul 15; 15 (14) : 4712-21.
Pubmed PMID: 19584166.
Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, Drezek RA. " Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. " Breast Cancer Res. Treat.. 2011 Jan ; 125 (1) : 27-34.
Pubmed PMID: 20217215.
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. " Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. " Oncogene. 2002 Oct 31; 21 (50) : 7680-9.
Pubmed PMID: 12400010.
Suo J, Snider SJ, Mills GB, Creighton CJ, Chen AC, Schiff R, Lloyd RE, Chang EC. " Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium. " Oncogene. 2011 Feb 10; 30 (6) : 724-36.
Pubmed PMID: 20890303.
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. " Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. " J. Clin. Oncol.. 2011 Jan 10; 29 (2) : 166-73.
Pubmed PMID: 21135276.
Osborne CK, Schiff R. " Mechanisms of endocrine resistance in breast cancer. " Annu. Rev. Med.. 2011 Feb 18; 62 : 233-47.
Pubmed PMID: 20887199.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. " Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. " J. Natl. Cancer Inst.. 2004 Jun 16; 96 (12) : 926-35.
Pubmed PMID: 15199112.
Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. " Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. " Cancer Res.. 2006 Aug 15; 66 (16) : 8266-73.
Pubmed PMID: 16912207.
Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. " Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. " J. Clin. Oncol.. 2005 Apr 10; 23 (11) : 2469-76.
Pubmed PMID: 15753463.
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. " Molecular profiles of progesterone receptor loss in human breast tumors. " Breast Cancer Res. Treat.. 2009 Mar ; 114 (2) : 287-99.
Pubmed PMID: 18425577.
Fu X, Huang C, Schiff R. " More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. " Breast Cancer Res.. 2011 ; 13 (2) : 307.
Pubmed PMID: 21575280.
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. " Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. " J. Clin. Oncol.. 2013 Apr 8;
Pubmed PMID: 23569315.
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. " Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. " J. Clin. Oncol.. 2005 Apr 10; 23 (11) : 2460-8.
Pubmed PMID: 15710948.
Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL. " New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. " Clin. Cancer Res.. 2003 Jan ; 9 (1) : 516S-23S.
Pubmed PMID: 12538509.
Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. " Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. " J. Natl. Cancer Inst.. 2000 Dec 6; 92 (23) : 1926-34.
Pubmed PMID: 11106684.
Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS. " PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells. " Cancer Cell. 2013 Jun 10; 23 (6) : 753-67.
Pubmed PMID: 23764000.
Sengupta S, Schiff R, Katzenellenbogen BS. " Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. " Breast Cancer Res. Treat.. 2009 Sep ; 117 (2) : 243-51.
Pubmed PMID: 18807177.
Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. " Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. " Clin. Cancer Res.. 2004 Jan 1; 10 (1) : 327S-330S.
Pubmed PMID: 14734487.
Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. " Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. " Breast Cancer Res.. 2008 ; 10 (6) : R105.
Pubmed PMID: 19087274.
Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. " Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. " Breast Cancer Res.. 2010 ; 12 (3) : R40.
Pubmed PMID: 20569503.
Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. " Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. " Clin. Cancer Res.. 2011 Mar 15; 17 (6) : 1351-61.
Pubmed PMID: 21138857.
Massarweh S, Schiff R. " Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. " Endocr. Relat. Cancer. 2006 Dec ; 13 : S15-24.
Pubmed PMID: 17259554.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. " Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. " J. Natl. Cancer Inst.. 2003 Mar 5; 95 (5) : 353-61.
Pubmed PMID: 12618500.
Xu J, Wan M, He Q, Bassett RL, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D. " SGK3 is associated with estrogen receptor expression in breast cancer. " Breast Cancer Res. Treat.. 2012 Jul ; 134 (2) : 531-41.
Pubmed PMID: 22576469.
Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. " Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. " Neoplasia. 2010 Sep ; 12 (9) : 718-26.
Pubmed PMID: 20824048.
Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S. " Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. " Mol. Cell. Biol.. 2010 Aug ; 30 (15) : 3827-41.
Pubmed PMID: 20516217.
Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. " ß1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. " Breast Cancer Res.. 2011 ; 13 (4) : R84.
Pubmed PMID: 21884573.
Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. " Systemic mirnas as potential biomarkers for malignancy. " Int. J. Cancer. 2012 Nov 15; 131 (10) : 2215-22.
Pubmed PMID: 22618667.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. " Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. " Cancer Res.. 2008 Feb 1; 68 (3) : 826-33.
Pubmed PMID: 18245484.
Lopez-Tarruella S, Schiff R. " The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. " Clin. Cancer Res.. 2007 Dec 1; 13 (23) : 6921-5.
Pubmed PMID: 18056165.
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. " The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. " Breast Cancer Res. Treat.. 2006 Aug ; 98 (3) : 315-27.
Pubmed PMID: 16541323.
Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ. " The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. " Proc. Natl. Acad. Sci. U.S.A.. 2011 Mar 1; 108 (9) : 3665-70.
Pubmed PMID: 21307310.
Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. " Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. " J. Natl. Cancer Inst.. 2007 May 2; 99 (9) : 694-705.
Pubmed PMID: 17470737.
Massarweh S, Schiff R. " Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. " Clin. Cancer Res.. 2007 Apr 1; 13 (7) : 1950-4.
Pubmed PMID: 17404074.
Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. " Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. " Breast Cancer Res. Treat.. 2012 Jul ; 134 (2) : 583-93.
Pubmed PMID: 22644656.
Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB. " Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. " Oncogene. 2005 Apr 28; 24 (19) : 3166-76.
Pubmed PMID: 15735693.